Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;36(3):216-21.
doi: 10.1016/j.ijantimicag.2010.04.014. Epub 2010 Jul 14.

Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones

Affiliations

Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones

Axel Dalhoff et al. Int J Antimicrob Agents. 2010 Sep.

Abstract

The objective of this study was to determine whether exposure of Staphylococcus aureus to early (ciprofloxacin or levofloxacin) and a recent fluoroquinolone (moxifloxacin) has differential potential as a mutator or selector for meticillin resistance. The potential of fluoroquinolones to act as mutators or selectors was studied in 24 strains each of healthcare-associated meticillin-susceptible S. aureus (MSSA) and meticillin-resistant S. aureus (MRSA) as well as 6 strains of community-acquired MRSA. Mutator or selector potential was studied first by exposing isolates to 0.5x the fluoroquinolone minimal inhibitory concentration (MIC) and screening for either single-step fluoroquinolone resistance or high-level oxacillin resistance; second, by exposing the heteroresistant MRSA P8 parent strain as well as fluoroquinolone-resistant subpopulations derived from strain P8 to constant fluoroquinolone concentrations ranging from 0.015 mg/L to 128 mg/L; and third, by exposing the heteroresistant MRSA population of strain P8 to fluctuating concentrations of ciprofloxacin, levofloxacin and moxifloxacin simulating oral doses of 500 mg twice a day, 500 mg once daily (qd) and 400mg qd, respectively, compared with amoxicillin/clavulanic acid 500 mg three times a day. Total viable counts and subpopulations resistant to 2x, 4x and 8x the fluoroquinolone MICs and to 32, 64 and 128 mg/L oxacillin [high-level oxacillin (hl-OXA)-resistant] were quantitated. None of the fluoroquinolones acted as a mutator; ciprofloxacin and levofloxacin selected for hl-OXA resistance, whereas moxifloxacin selected towards hl-OXA resistance by one order of magnitude less frequently. The P8 parent and fluoroquinolone-resistant subpopulations were eliminated by ciprofloxacin or levofloxacin concentrations >10-fold higher than the MICs, whereas moxifloxacin eliminated all subpopulations by concentrations 2-3-fold the MIC. Finally, exposure of P8 to fluctuating amoxicillin/clavulanic acid, ciprofloxacin and levofloxacin concentrations, respectively, caused a rapid selection of fluoroquinolone and hl-OXA resistance. Moxifloxacin reduced total viable counts rapidly, thus preventing the emergence of resistant subpopulations. In conclusion, fluoroquinolones do not act as mutators towards hl-OXA resistance. However, ciprofloxacin and levofloxacin are potent selectors of hl-OXA resistance, whereas moxifloxacin is a poor selector. In contrast to ciprofloxacin and levofloxacin, moxifloxacin exerts a high bactericidal activity against staphylococci, thus minimising the probability for selection of resistance. Thus, fluoroquinolones exert a dichotomous MRSA-selective potential in heteroresistant MRSA.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

LinkOut - more resources